Prophylaxis and Treatment of CMV Infections in Transplantation

  • John A. Zaia
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

Human cytomegalovirus [CMV] infection is a common occurrence in persons with or without immunocompromising diseases or treatments, but CMV rarely produces disease in the immunocompetent individual1 When disease does occur it is usually associated with unusual situations such as fetal life, post-trauma or post-surgical exposure to primary CMV infection, or in the young adult with children in day-care.2 Thus, in normal persons, symptomatic disease occurs only following primary infection, and the most severe diseases are only seen in association with other compromising medical conditions. This is true also in recipients of marrow or solid organ transplants in which primary infection and degree of immunocompetence are the most important factors for determining outcome

Keywords

Transplant Recipient Liver Transplant Recipient Cytomegalovirus Infection Oral Acyclovir Cytomegalovirus Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zaia JA. Epidemiology and Pathogenesis of Cytomegalovirus Disease. Semin Hematol 1990; 27: 5–10PubMedGoogle Scholar
  2. 2.
    Ho M. Cytomegalovirus: Biology and Infection. Second ed. New York: Plenum; 1991.Google Scholar
  3. 3.
    Meyers JD, Flournoy N, Thomas ED. Cytomegalovirus infection and specific cell-mediated immunity after marrow transplantation. J Infect Dis 1980; 142: 816–824CrossRefPubMedGoogle Scholar
  4. 4.
    Grundy JE, Lui SF, Super M et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988;ii:132135Google Scholar
  5. 5.
    Bowden RA, Slichter SJ, Sayers MH, et al. Use òf leukocyte-depleted platelets and cytomegalovirus–seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246–250PubMedGoogle Scholar
  6. 6.
    Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478–488CrossRefPubMedGoogle Scholar
  7. 7.
    Rubin RH. Infection in the renal and liver transplant patient. Clinical approach to infection in the compromised host, Second Edition. Rubin RH, Young LS, ed. New York: Plenum; 1988. p. 53.Google Scholar
  8. 8.
    Rook AH, Quinnan GV, Frederick WJR et al. Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. Am J Med 1984; 76: 385–392CrossRefPubMedGoogle Scholar
  9. 9.
    Quinnan GV, Kinnani N, Rook AH et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T lymphocyte and non-T lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus in bone marrow recipients. N Engl J Med 1982; 307: 7–13CrossRefPubMedGoogle Scholar
  10. 10.
    Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373–1380PubMedGoogle Scholar
  11. 11.
    Boland GJ, Hene RI, Ververs C, DeHaan MAM(DeGase GC. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation. Clin Exp Immunol 1993; 94: 306–312CrossRefPubMedGoogle Scholar
  12. 12.
    Meyers JD, Fluornoy N. Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation. A review of ten years’ experience. Rev Infect Dis 1982; 4: 1119–1132CrossRefPubMedGoogle Scholar
  13. 13.
    Rubin RH, Cosimi AB, Tolkoff-Rubin NE, Russel PS. Hirsch MS. Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 1977; 24: 458–464CrossRefPubMedGoogle Scholar
  14. 14.
    Betts RF, Freeman RB, Douglas Jr. RG et al. Clinical manifestations of renal allograft derived primary cytomegalovirus infection. Am J Dis Child 1982; 131: 759–763Google Scholar
  15. 15.
    Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovinis pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992; 146: 1419–1425CrossRefPubMedGoogle Scholar
  16. 16.
    Gorensek M1, Stewart RW, Keys TF, McHenry MC, Goormastic M. A multivariate analysis of the risk of cytomegalovirus infection in heart transplant recipients. J Infect Dis 1988; 157: 515–522CrossRefGoogle Scholar
  17. 17.
    Dunn DL; Gillingham K1; Kramer MA et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis for cytomegalovirus infection after solid organ transplantation. Transplantation. 1994; 57: 876–884.CrossRefPubMedGoogle Scholar
  18. 18.
    Schmidt GM, Horak DA, Niland JC et al. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324: 1005–1011CrossRefPubMedGoogle Scholar
  19. 19.
    Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand? Blood 1994; 83: 2392–2398PubMedGoogle Scholar
  20. 20.
    Pecego R, Hill R, Appelbaum FR et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986; 42: 515–517CrossRefPubMedGoogle Scholar
  21. 21.
    Valteau D, Harmann O, Benhamou E et al. Nonbacterial, nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without total-body irradiation. Transplantation 1988; 45: 737–740CrossRefPubMedGoogle Scholar
  22. 22.
    Ljungman P, Biron P, Bosi A et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Bone Marrow Transplantation. 1994; 13: 209–212.PubMedGoogle Scholar
  23. 23.
    Griffiths RI, Bass EB, Powe NR et al. Factors influencing third party payer costs for allogeneic bone marrow transplant. Bone Marrow Transplant 1993; 12: 43–48PubMedGoogle Scholar
  24. 24.
    Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705–712CrossRefPubMedGoogle Scholar
  25. 25.
    Ackerman JR, LeForce WM, Weinstein S et al. Four-year experience with exclusive use of cytomegalovirus antibody negative donors for CMV-Ab-negative kidney recipients. Transplant Proc. 1988;20 Suppl 1, 469–471.Google Scholar
  26. 26.
    Meyers JD, Reed EC, Shepp DH et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70–75CrossRefPubMedGoogle Scholar
  27. 27.
    Balfour Jr. HH, Chace BA, Stapleton JT et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381–1387CrossRefPubMedGoogle Scholar
  28. 28.
    Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601–1607CrossRefPubMedGoogle Scholar
  29. 29.
    Stratta RJ, Shaefer MS, Cushing KA et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg. 1992; 127: 55–64.CrossRefPubMedGoogle Scholar
  30. 30.
    Legendre C, Ducloux D, Ferroni A, Chkoff N, Geffrier C, Rouzioux C, Kreis H. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study. J Med Viral 1993;Suppl 1: 118–122Google Scholar
  31. 31.
    Saliba F, Eyraud D, Samuel D, David MR, Arulnaden JL, Dussaix E, Mathieu D, Bismuth H. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc. 1993; 25: 1444–1445.PubMedGoogle Scholar
  32. 32.
    Cole NL, Balfour Jr, MI. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis. 1987; 6: 255–261.CrossRefPubMedGoogle Scholar
  33. 33.
    Merigan TC, Renlund DB, Keay Set al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Eng J Med. 1992; 326: 1182–1186.CrossRefGoogle Scholar
  34. 34.
    Cohen AT, O’Grady JG, Sutherland Set al. Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults. J Med Virol. 1993; 40: 5–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Nakazato PZ, Burns W, Moore P, Garcia-Kennedy R, Cox K, Esquivel C. Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and ganciclovir. Transplant Proc. 1993; 25: 1935–1937.PubMedGoogle Scholar
  36. 36.
    Singh N, Yu VL; Mieles L et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med. 1994; 120: 375381.Google Scholar
  37. 37.
    Zaia JA, Levin MJ, Leszczynski J, Wright GG, Grady GF. Cytomegalovirus immune globulin: production from selected normal donor blood. Transplantation 1979; 27: 66–67CrossRefPubMedGoogle Scholar
  38. 38.
    Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317: 1049–1054CrossRefPubMedGoogle Scholar
  39. 39.
    Werner BG, Snydman DR, Freeman R et al. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. Transplant Proc 1993; 25: 1441–1443PubMedGoogle Scholar
  40. 40.
    Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990; 162: 373–380CrossRefPubMedGoogle Scholar
  41. 41.
    Miller WJ, McCullough 1, Balfour HE Jr. et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7: 227–234PubMedGoogle Scholar
  42. 42.
    Bowden RA, Sayers MH, Cays M, Slichter SJ. The role of blood product filtration in the prevention of transfusion associated cytomegalovirus infection after marrow transplant. Transfusion 1989; 29: 5205Google Scholar
  43. 43.
    Zaia JA. Cytomegalovirus infection. Forman SJ, Blume KG, Thomas ED. Bone Marrow Transplantation. Boston: Blackwell Scientific Publications; 1994. p. 376–403.Google Scholar
  44. 44.
    Boland, GH; Vlieger AM, Ververs C, De Gast GC. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation. Clin Exp Immunol. 1992; 88: 506–511.CrossRefPubMedGoogle Scholar
  45. 45.
    Li C, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971–1979PubMedGoogle Scholar
  46. 46.
    Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994; 343: 749–753CrossRefPubMedGoogle Scholar
  47. 47.
    Atkinson K, Downs K, Golenia M et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br J Hematol 1991; 79: 57–62CrossRefGoogle Scholar
  48. 48.
    Yau JC, Dimopoulos MA, Huan SD et al. Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. Eur J Haematol 1991; 47: 371–376CrossRefPubMedGoogle Scholar
  49. 49.
    Goodrich JM, Bowden RA, Fisher L et al. Prevention of cytomegalovirus disease after allogeneic marrow transplant by ganciclovir prophylaxis. Ann Intern Med 1993; 118: 173–178CrossRefPubMedGoogle Scholar
  50. 50.
    Winston DJ, Ho WG, Barton K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179–184CrossRefPubMedGoogle Scholar
  51. 51.
    von Bueltzingsloewen A, Bordigoni P, Witz F et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 197–202Google Scholar
  52. 52.
    Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166: 473–479CrossRefPubMedGoogle Scholar
  53. 53.
    Ruutu P, Ruutu T, Volin L et al. Cytomegalovirus is frequently isolated in bronchoalveolar lavage fluid of bone marrow transplant recipients without pneumonia. Ann Intern Ivied 1990; 112: 913–916CrossRefGoogle Scholar
  54. 54.
    Singh N, Yu VL, Mieles L et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med 1994; 120: 375381Google Scholar
  55. 55.
    Gleaves CA, Smith TF, Shuster EA, Pearson GR. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol 1985; 21: 217–221PubMedGoogle Scholar
  56. 56.
    van der Bij W, Torensma R, vanSon WJ et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 1988; 25: 17–188CrossRefGoogle Scholar
  57. 57.
    Grefte JMM, van der Gun BTF, Schmolke S et al. Cytomegalovirus antigenemia assay: identification of the viral antigen as the lower matrix protein pp65. J Infect Dis 1992; 166: 683–684CrossRefPubMedGoogle Scholar
  58. 58.
    Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358–1364PubMedGoogle Scholar
  59. 59.
    Saltzman RL, Quirk MR, Jordan MC. High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Invest 1992; 90: 1832–1838CrossRefPubMedGoogle Scholar
  60. 60.
    Demmler GJ, Buffone GJ, Schimbor CM. May RA. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis 1988; 158: 1177–1184CrossRefPubMedGoogle Scholar
  61. 61.
    Cassol SA, Poon M, Pal R et al. Primer-mediated enzymatic amplification of cytomegalovirus (CMV) DNA. J Clin Invest 1989; 83: 1109–1115CrossRefPubMedGoogle Scholar
  62. 62.
    Hsia K, Spector DH, Lawrie J, Spector SA. Enzymatic amplification of human cytomegalovirus sequences by polymerase chain reaction_ 1 Clin Microbiol 1989; 27: 1802–1809Google Scholar
  63. 63.
    Wolf DG, Spector SA. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 1993; 56: 330–334CrossRefPubMedGoogle Scholar
  64. 64.
    van den Berg AP, van Son WJ, Haagsma EB et al. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. Transplantation. 1993; 55: 847–851.CrossRefPubMedGoogle Scholar
  65. 65.
    Einsele H, Ehninger G. Steidle M et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 1991; 2. 1170–1172CrossRefGoogle Scholar
  66. 66.
    Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 1991; 77: 1104–1110PubMedGoogle Scholar
  67. 67.
    Jiwa NM, van Geniert GW, Raap AK et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes in viremic transplant recipients by the polymerase chain reaction. Transplantation 1989; 48: 72–76CrossRefPubMedGoogle Scholar
  68. 68.
    Boland GJ, de Weger RA, Tilanus MGJ, Ververs C. Bosboom-Kalsbeek K, de Gast GC. Detection of cytomegalovirus (CMV) in gransulaocytes by polymerase chain reaction compared with the CMV antigen test. J Clin Microbiol 1992; 30: 1763–1767PubMedGoogle Scholar
  69. 69.
    Ishigaki S, Takeda M. Kura T, Ban N, Saitoh T. Cytomegalovirus DNA in the sera of patients with cytomegalovirus pneumonia. Br J Haematol 1991: 79: 198–204CrossRefPubMedGoogle Scholar
  70. 70.
    Brytting M, Xu W, Wahren B, Sundqvist VA. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol 1992; 30: 1937–1941PubMedGoogle Scholar
  71. 71.
    Spector SA, Merrill R, Wolf D, Dankner WM. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 1992; 30: 2359–2365PubMedGoogle Scholar
  72. 72.
    Aspin MM, Gallez-Hawkins GM, Giugni TD et al. Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipients. J Clin Microbiol 1994; 32: 2266–2269.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • John A. Zaia

There are no affiliations available

Personalised recommendations